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The rising incidence adenocarcinomas of the region around esophago–gastric 
junction have become an important clinical topic.  
 
Adenocarcinoma of the distal esophagus, once an unusual malignancy, is 
diagnosed with increasing frequency and now accounts for over 50 percent of 
esophageal cancers in our country. The gross appearance resembles that of squamous 
cell carcinoma. Microscopically, adenocarcinoma almost always originates in 
metaplastic Barrett's mucosa, and resembles gastric cancer. The most important 
etiologic factor is a metaplastic columnar-lined or Barrett's esophagus, which occurs as 
a complication in approximately 10 percent of patients with gastroesophageal reflux 
disease. The incidence of adenocarcinoma in a patient with Barrett's esophagus when 
studied prospectively is 1 in 100 patient years of follow-up - at least 30 to 40 times that 
expected for a similar population without Barrett's esophagus. This risk is similar to the 
risk for developing lung cancer in a person with a 20 pack per year history of smoking.  
 
Gastric carcinoma is the most common cancer worldwide and is now surpassed 
only by lung cancer in incidence .There has been a noticeable shift in the site of gastric 
cancer from the distal stomach to the more proximal stomach over the past several 
decades. The incidence of adenocarcinoma of the gastric cardia has increased steadily 
while the incidence of cancer in other anatomic subsites has decreased. The increase is 
possibly linked to a history of smoking, obesity, food practices or heavy alcohol use. 
 
Over the past, the discussions of gastroesophageal junction tumors have been 
overshadowed by confusion about the type of junctional tumors. Following a consensus 
conference of the International Society for Diseases of the Esophagus (ISDE) and the 
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International Gastric Cancer association (IGCA) an agreement has been achieved for 
classification of adenocarcinomas arising in the area of the esophago–gastric junction 
.This classification is based on topographic anatomic characteristics and the location of 
the tumor center above, at, or below the gastric cardia as suggested by Siewert et al. 
The anatomical landmark (fig 1) that remains at the center of this anatomical 
classification is the endoscopic ‘cardia’, defined as the oral end of the typical 
longitudinal gastric mucosa folds. In AEG Type I the tumor is located above this 
endoscopically defined cardia, in AEG Type II the tumor center or tumor mass is in the 
area of the endoscopic cardia, in AEG Type III the tumor. These cancers are generally 
considered to be biologically aggressive; with overall 5-year survival rates below 10% 
.Surgical resection is the mainstay of therapy in patients with invasive adenocarcinoma 
who are fit for surgery. Complete removal of the primary tumor and its lymphatic 
drainage has to be the primary goal of any surgical approach to adenocarcinoma of the 
gastroesophageal junction. 
 
 This study is an audit of the AEG managed in GRH. An attempt is made to 
identify the factors to improve the outcome of these patients. 
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REVIEW OF LITERATURE 
2.1 TISSUE COMPOSITION OF THE ESOPHAGUS, GE JUNCTION AND STOMACH 
Review of 
Literature 
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ESOPHAGUS( fig 2) 
95Tunica Mucosa  
Squamous epithelium is of the stratified, nonkeratinizing type. It covers the tubular
esophagus. 
Lamina Propria Mucosa 
It consists of connective tissue built up of areolar, elastic and collagenous fiber 
networks. Esophageal mucosa contains exclusively alveolar serous glands, follicles, 
esophageal glands of mucous type, and, in the terminal esophagus, glands that 
resemble cardiac glands. Projecting into the epithelium, the layer forms the papillae. 
Lamina Muscularis Mucosa 
The lamina muscularis mucosa is a thin layer of short smooth muscle bundles.  
Tela Submucosa 
The fatty and relatively thick submucosa permits considerable mobility of the 
esophageal mucosa. The submucosa contains the mucous glands, blood vessels, the 
Meissner neural plexus, and an extensive lymphatic network.  
 
Tunica Muscularis 
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The muscle of the esophagus consists longitudinally arranged outer layer and a 
transverse inner layer. Between the two muscular layers is a thin intramuscular septum 
of connective tissue that contains fine blood vessels and ganglion cells (Auerbach 
plexus). The esophagus  lacks a serosa and is surrounded by a layer of loose 
fibroalveolar adventitia 
GASTRIC WALL 
Serosa 
The serosa is nothing more than the peritoneum, a thin layer of loose connective tissue 
underlying a layer of simple squamous mesothelium. 
Muscular Layer 
Three well-known layers of musculature: an outer longitudinal layer, middle circular 
layer, and inner oblique layer. The surgeon considers the three layers as one in the 
operating room 
Submucosal Layer 
Called the "vascular layer" ,the submucosa is composed of loose, areolar connective 
tissue which connects the mucosa to the external musculature.  
Mucosal Layer95 
 
 
FIG :2 :tissue organization 
of the  esophagus   
the esophagogastric junction 
(EGJ)
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2.2 ANATOMY 
2.2.1 SURGICAL ANATOMY OF THE ESOPHAGUS 
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Position of the Esophagus 
 It begins where the pharynx ends at the level of the C-6 vertebra and ends at the 
cardia of the stomach, some 3 to 5 cm below the diaphragm opposite the twelfth 
thoracic vertebra. The esophagus is a midline structure anterior to the spine and 
posterior to the trachea. It passes into the thorax at the level of the sternal notch and 
travels caudally within the chest in the posterior mediastinum. The esophageal hiatus of 
the diaphragm is at the level of the tenth thoracic vertebra95.  
Designations of the Esophagus 
The esophagus has been classified from three different medical perspectives: classical 
anatomy, function, and surgical understanding. (fig 3) 
Classical anatomy divides the esophagus into three parts: 
1. Cervical 
2. Thoracic 
3. Abdominal 
 
Surgeons can benefit from viewing the esophagus as a two-part structure divided 
into proximal and distal segments bordering at the tracheal bifurcation .This approach 
best matches surgical needs and therapeutic strategies. There are three reasons for this 
approach95: 
13 | P a g e  
 
(1) Antipodal lymphatic flow proceeds from the area of the tracheal bifurcation cranially 
and caudally. This affects the direction of early lymphatic tumor spread and the 
procedures of lymphadenectomy. 
(2). The prognosis for distal tumors is far better than that for the rarer tumors located in 
the proximal half of the esophagus. Proximal tumors also rapidly perforate the 
esophageal wall to invade adjacent structures such as the trachea, bronchi, and 
adjacent spaces such as the mediastinum.  
(3) This classification conforms with the embryologic development from two different 
tissue sources and the specific arrangement of vessels, muscle types, and innervation.  
LOWER ESOPHAGEAL SPHINCTER 
 
LES 95is located at the terminal end of the esophagus and represents the distal 3 
to 5 cm of the organ. Most of the LES lies within the abdominal cavity. A small 
condensation of circular smooth-muscle fibers resides in this region, too indefinite to 
constitute an anatomical sphincter. The specialized nature and unique innervation of the 
smooth muscle of the terminal esophagus provide the basis for a physiological 
sphincter. The LES is a high-pressure zone interposed between the body of the 
esophagus and the cardia of the stomach .Normally, a mean pressure of 20 ± 5mmHg 
is maintained at all times except during swallowing, when the pressure falls to 0mmHg, 
allowing esophageal peristalsis to empty the swallowed food into the stomach. In its 
resting state, therefore, the high pressure of the LES prevents reflux of gastric contents 
into the esophagus.  
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 ARTERIAL SUPPLY 
 
The esophagus96 is nourished by numerous segmental arteries( fig 7).  The 
cervical esophagus receives blood from the superior thyroid artery as well as the inferior 
thyroid artery of the thyrocervical trunk, with both sides communicating through 
collateral vessels. The major blood supply of the thoracic esophagus is from four to six 
aortic esophageal arteries, supplemented by collateral vessels from the inferior thyroid, 
intercostal and bronchial, inferior phrenic and left gastric arteries. The extensive venous 
drainage of the esophagus includes the hypopharyngeal, azygous, hemiazygous, 
intercostal, and gastric veins. 
 
LYMPHATIC DRAINAGE 
 
The esophagus has an extensive lymphatic drainage that consists of two 
lymphatic plexuses, one arising in the mucosa and the other in the muscular layer. 
Mucosal lymphatic capillaries pierce the muscular layer and drain to regional lymph 
nodes. These lymphatic capillaries run longitudinally in the esophageal wall before they 
exit through muscle into adjacent lymph nodes. The flow of lymphatics of the upper two 
thirds of the esophagus tends to be upward, whereas the distal third tends to be 
downward; however, all lymphatics intercommunicate. Therefore, esophageal 
carcinomas may spread directly to internal jugular nodes in the neck, paratracheal 
nodes in the superior mediastinum, subcarinal nodes in the middle chest, 
paraesophageal nodes in the lower mediastinum, and inferior pulmonary ligament, 
perigastric, and left gastric artery lymph nodes96. 
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Fig 4 : Divisions, terminology, and relationships of the 
Fig 3: Arterial supply of the Esophagus 
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2.2.2 SURGICAL ANATOMY OF THE STOMACH 
GROSS ANATOMY 
 
Wallace P. Ritchie, Jr., called the stomach an elegant organ, once thought to be 
the seat of the soul, always handy to bring to the dinner table, and a recognized source 
of ecstasy and grief96.  
 
The most proximal region of the stomach is called the cardia, and it attaches to 
the esophagus. Immediately proximal to the cardia is a physiologically competent lower 
esophageal sphincter. Distally, the pylorus connects the distal stomach (antrum) to the 
proximal duodenum. Although the stomach is fixed at the gastroesophageal (GE) 
junction and the pylorus, its large mid portion is mobile. The fundus represents the 
superior-most part of the stomach and is floppy and distensible. It is bounded superiorly 
by the diaphragm and laterally by the spleen. The body of the stomach represents the 
largest portion and is also referred to as the corpus. The body also contains most of the 
parietal cells and is bounded on the right by the relatively straight lesser curvature and 
on the left by the longer greater curvature. At the angularis incisura, the lesser curvature 
abruptly angles to the right. It is at this point that the body of the stomach ends and the 
antrum begins. 
 
Another important anatomic angle (angle of His) is that which the fundus forms 
with the left margin of the esophagus. Most of the stomach resides within the left upper 
quadrant of the abdomen. The left lateral segment of the liver usually covers a large 
portion of the stomach anteriorly. The diaphragm, chest, and abdominal wall bound the 
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remainder of the stomach. Inferiorly, the stomach is attached to the transverse colon, 
spleen, caudate lobe of the liver, diaphragmatic crura, and retroperitoneal nerves and 
vessels. Superiorly, the GE junction is found about 2 to 3 cm below the diaphragmatic 
esophageal hiatus in the horizontal plane of the seventh chondrosternal articulation, a 
plane only slightly cephalad to that containing the pylorus. The gastrosplenic ligament 
attaches the proximal greater curvature to the spleen. 
 
BLOOD SUPPLY 
 
Most of the blood supply96 to the stomach ( fig 5) is from the celiac artery. There 
are four main arteries: the left and right gastric arteries along the lesser curvature and 
the left and right gastroepiploic arteries along the greater curvature. In addition, a 
substantial quantity of blood may be supplied to the proximal stomach by the inferior 
phrenic arteries and by the short gastric arteries from the spleen. The largest artery to 
the stomach is the left gastric artery, and it is not uncommon (15% to 20%) for an 
aberrant left hepatic artery to originate from it. The right gastric artery arises from the 
hepatic artery (or the gastroduodenal artery). The left gastroepiploic artery originates 
from the splenic artery, and the right gastroepiploic originates from the gastroduodenal 
artery. The extensive anastomotic connection between these major vessels ensures 
that, in most cases, the stomach will survive if three of four arteries are ligated, provided 
that the arcades along the greater and lesser curvatures are not disturbed. In general, 
the veins of the stomach parallel the arteries. The left gastric (coronary) and right gastric 
veins usually drain into the portal vein. The right gastroepiploic vein drains into the 
superior mesenteric vein, and the left gastroepiploic vein drains into the splenic vein.  
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LYMPHATIC DRAINAGE 
 
Generally, the lymphatic drainage96 (fig 6)of the stomach parallels the 
vasculature and essentially drains into four zones of lymph nodes as depicted in. The 
superior gastric group drains lymph from the upper lesser curvature into the left gastric 
and paracardial nodes. The suprapyloric group of nodes drains the antral segment on 
the lesser curvature of the stomach into the right suprapancreatic nodes. The 
pancreaticolienal group of nodes drains lymph high on the greater curvature into the left 
gastroepiploic and splenic nodes. The inferior gastric/subpyloric group of nodes drains 
lymph along the right gastroepiploic vascular pedicle. All four zones of lymph nodes 
drain into the celiac group and into the thoracic duct. Although the aforementioned 
lymph nodes drain different areas of the stomach, it remains widely recognized that 
gastric cancers may metastasize to any of the four nodal groups regardless of the 
cancer location. In addition, the extensive submucosal plexus of lymphatics accounts for 
the fact that there is frequently microscopic evidence of malignant cells several 
centimeters from the resection margin of gross disease. 
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Fig 5: Blood Supply of the Stomach. 
Fig 6 :Lymphatic drainage of the Stomach. 
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2.3.3 ANATOMY OF THE GE JUNCTION 
 
The GE junction consists95 of the distal esophagus, esophageal hiatus, and 
proximal stomach. The esophagus joins the stomach in the abdomen, just below the 
diaphragm. The length of the abdominal esophagus is from 0.5 to 2.5 cm. 
Its relationships to surrounding structures are: 
 
Anterior: Posterior surface of left lobe of liver
Posterior: Right crus of diaphragm, aorta 
Right: Caudate (spigelian) lobe of liver 
Left: Fundus of stomach 
Points of Clinical and Surgical Relevance 
The transition between the squamous esophageal and columnar gastric 
epithelium is an objectively recognizable reference point. This abrupt, serrated line, 
known as the Z-line, has "four to six small, long or short tongues."  It is normally located 
near the gastric orifice or just above it. Endoscopists thus base their determination on 
differences in color, the degree of transparency of the epithelium, mucosal structure, 
and epithelial thickness. Any proximal shift of gastric- or intestinal-type columnar 
epithelium into the esophagus is considered pathological. The change results from long-
lasting gastroesophageal reflux that causes chronic damage to the esophageal mucosa.  
The ultimate result may be that "the distal esophagus to a greater or lesser extent is 
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circumferentially lined by columnar epithelium transformed to the gastric or intestinal 
type. This pathology, called Barrett's esophagus, is regarded as a precancerous 
condition. 
The histologic junction between the esophagus and stomach is not coincident 
with the external junction. In the cadaver, this epithelial junction lies about 1 cm above 
the external gross junction. Above the boundary, islands of columnar gastric epithelium 
may be present at all levels of the esophagus. Such heterotopic patches are not 
pathologic.  
In the living patient, identification of the line of transition between esophagus and 
stomach is more complicated than in the cadaver. The submucosal tissue is so loose 
that the mucosa moves freely over the underlying muscularis, bulging in folds into the 
stomach at each swallow. Even at rest, the junctional level can change. Palmer, using 
silver markers on the epithelial boundary, found that the junction was lower in the full 
stomach than in the empty one. 
The mucosa that lines the cardia of the stomach is distinct from the rest of the 
stomach. Its glands are mucus-secreting, without chief or parietal cells. These are the 
cardiac glands of the histologist. Hayward opposed the use of the word cardia, and 
characterizes terms derived from it as "insufferably vague." He suggested the term 
"junctional epithelium" for this area between the typical esophageal and typical gastric 
mucosae. 
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FIG 7 :Lymphatic drainage of the GE junction. 
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It has been hypothesized that the presence of cardiac mucosa at the 
gastroesophageal junction represents an early histologic manifestation of 
gastroesophageal reflux. 
2.3 EPIDEMIOLOGY 
Over the past quarter century, we have seen a shift in both the lethality and 
location of gastric cancers. Although distal gastric cancers have become rare the 
incidence of adenocarcinomas of the proximal stomach and distal esophagus has 
risen1-3. The behavior of these proximal tumors makes them an unique entity. The 
pliability of the gastric cardia as well as the deep location of the gastroesophageal 
junction, often masks the vague symptoms caused by early-stage lesions. Furthermore, 
due to the strategic location at the crossroads of two major body cavities, lymphatic 
spread occurs in two directions4—proximally into the mediastinum and distally to the 
celiac lymph nodes. Thus, these tumors often present at a relatively advanced stage5. 
 
Symptoms and signs 
Occasional tobacco use 
Variable alcohol consumption 
Modest weight loss, if any 
Robust body habitus 
Mild dysphagia, rare odynophagia 
Long-standing history of esophageal reflux and, often, recent improvement 
in reflux symptoms 
Frequent cardiovascular comorbidity  
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2.4 PATHOLOGY 
Barrett’s Esophagus 
 
The British surgeon, Norman Barrett, first described the phenomenon of 
columnar epithelial metaplasia98 of the normally squamous esophageal mucosa in1950. 
He first surmised that congenital rests of columnar epithelium accounted for these 
findings. It is now universally acknowledged that the process is related to injury and 
healing in the lower esophagus and, thus, it is an adaptation rather than a congenital 
anatomic aberration. Although Barrett’s changes are frequent in patients with reflux 
symptoms, 40% of patients with Barrett’s changes have minimal or no reflux symptoms. 
The association of Barrett’s mucosa with adenocarcinoma place cancer risk in Barrett’s 
in the range of 2-4%. This risk is higher with the type of Barrett’s changes termed 
special columnar epithelium, as opposed to the cardiac and fundic histologic variety of 
Barrett’s, although the former’s substantial risk appears to be related to the higher risk 
of dysplasia with specialized columnar Barrett changes. Of great concern is the finding 
that correction of reflux by medical or surgical measures is frequently unsuccessful in 
reversing Barrett’s changes and reducing the cancer risk. Blot et al’s observations about 
increasing adenocarcinoma of the lower esophagus and observations that Barrett’s 
mucosal changes are found in as many as 65% of patients with adenocarcinoma have, 
appropriately, focused a great deal of investigation into the causes and modification of 
these changes. Reversal of advanced Barrett’s changes seldom occurs, whether the 
condition is managed medically using inhibitors of gastric acid production and 
prokinetics to stimulate gastric emptying or whether it is managed surgically with 
antireflux surgery. 
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 For the present, however, the major focus is placed on careful follow-up 
of patients found to have Barrett’s metaplasia. Subsequent endoscopic biopsies are 
performed to determine if any dysplasia has developed. Severe dysplasia merits 
consideration of prophylactic intervention. 
 
MICROSCOPY 
 
 
 The microscopic characteristics of GE junctions tumors show grade 2 to grade 3 
differentiation. Signet ring cells are present in both distal esophageal and proximal 
gastric tumors. There is microscopic evidence of barett’s epithelium, especially type 1 
tumors. 
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STAGING 
T: 
Primary Tumor 
 
Esophagus and cardia Stomach 
TX Tumor cannot be assessed Primary tumor cannot be assessed 
T0 No evidence of tumor No evidence of primary tumor 
Tis High-grade dysplasia 
Carcinoma in situ: 
intraepithelial tumor 
without invasion of the 
lamina propria 
T1 
Tumor invades the lamina propria, 
muscularis mucosa, or submucosa; 
does not breach the submucosa 
Tumor invades lamina 
propria or submucosa 
T2 Tumor invades into but not beyond the muscularis propria 
Tumor invades muscularis 
propria or subserosa 
T3 
Tumor invades the paraesophageal 
tissue but does not invade adjacent 
structures 
Tumor penetrates serosa 
(visceral peritoneum) 
without invasion of 
adjacent structures 
T4 Tumor invades adjacent structures  
Tumor invades adjacent 
structures 
N: Regional 
Lymph Nodes   
NX Regional lymph nodes cannot be assessed 
Regional lymph node(s) 
cannot be assessed 
N0 No regional lymph node metastases  
No regional lymph node 
metastasis 
N1 Regional lymph node metastases  
Metastasis in 1 to 6 
regional lymph nodes 
  Metastasis in 7 to 15 regional lymph nodes 
  Metastasis in more than 15 regional lymph nodes 
M: Distant 
Metastases   
MX Distant metastases cannot be assessed 
Distant metastasis cannot 
be assessed 
M0  No distant metastasis 
M1a Lower thoracic esophagus metastatic to celiac lymph nodes Distant metastasis 
M1b 
Lower thoracic esophagus metastatic 
to other nonregional lymph nodes or 
other distant sites 
 
27 | P a g e  
 
Stage 
Groupings 
T 
 
N 
 
M 
 
T 
 
N 
 
M 
 
Stage 0 Tis N0 M0 Tis N0 M0 
Stage IA T1  
N0 
 
M0 
 T1 N0 M0 
Stage IB  
 
 
 
 
 
T1 
T2a/b 
N1 
 N0 
M0 
 M0 
Stage IIA T2 T3 
N0 
N0 
M0 
M0 
T1 
T2a/b 
T3 
N2 
N1 
N0 
M0 
M0 
M0 
Stage IIB T3 T4 
N1 
Any N 
M0 
M0    
Stage III A T1 T2 
N1 
N1 
M0 
M0 
T2a/b 
T3 
T4 
N2 
N1 
N0 
M0 
M0 
M0 
Stage III B    T3 N2 M0 
Stage IV A Any T Any N M1a 
T4 
T1–3 
Any T 
N1–3 
N3 
Any N 
M0 
M0 
M1 
Stage IV B Any T Any N M1b    
      
From Rice TW: Esophageal carcinoma: Diagnosis and staging of esophageal carcinoma. In 
Pearson FG, Cooper JD, Deslauriers J, et al (eds): 
Esophageal Surgery, 2nd ed. Philadelphia, Churchill Livingstone, 2002, p 686. 
From AJCC Cancer Staging Manual, 6th ed. New York, Springer-Verlag, 2001. 
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2.6 PREOPERATIVE STAGING 
 
Perhaps even more important than defining the subtype of gastroesophageal 
junction tumor is accurate pretreatment staging. Surgical resection offers the only 
chance for cure, and most patients undergoing R1 (residual microscopic disease) or R2 
(residual macroscopic disease) resections could just as easily have been palliated with 
a combination of chemotherapy, radiation, and endoluminal stenting. Hence, 
determining both the extent of disease and local respectability is an essential step 
before commencing any type of therapy.  
 
ENDOSCOPY AND BIOPSY (fig 8) 
 
  Preoperative endoscopy is usually the first test performed in diagnosing and 
staging the lesion. The findings on endoscopy are critical in determining the length and 
circumferential extension as well as the degree of obstruction the lesion causes, 
proximal extent of resection and ultimately dictate the appropriate operative approach. 
The extent of transmural invasion,however, is poorly evaluated . The presence or 
absence of Barrett’s esophagus should be assessed carefully. Multiple biopsies must be 
obtained from the lesion and adjacent or suspicious mucosa. 
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BARIUM SWALLOW (fig 9) 
 
 Useful in indicating the extent of the lesion, the barium swallow test can also 
provide the extent of any luminal narrowing and any angulation of the axis of the 
esophagus.  
 
COMPUTERIZED TOMOGRAPHIC SCAN OF CHEST AND ABDOMEN 
 
 
This is the current standard to evaluate both the extent of local disease as well 
as to search for hepatic, pulmonary, nodal, and other metastases. A 64 slice CT scan 
and 256 slice CT scan comes in handy and most of the time dispels the need for barium 
studies 
 
ENDOSCOPIC ULTRASOUND( fig 10) 
 
EUS is currently the most reliable method available for clinical staging15 of 
esophageal or esophagogastric carcinomas that do not have distant disease on CT 
scan. The accuracy of EUS for T staging ranges between 75% and 90%16,17 . Given that 
the stage of the tumor affects the extent of resection, EUS is an important adjunct to 
preoperative planning. In one recent review, EUS was superior to CT scan for staging of 
esophageal cancer18.  CT, however, remains superior to EUS for detecting distant 
lymph node metastases such as at the celiac axis 19or the supraclavicular region20.  
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POSITRON EMISSION TOMOGRAPHY (PET) (fig 11) 
 
 
FDG PET is not an appropriate first-line diagnostic procedure in the detection of 
stomach cancer and is not helpful in tumor staging, it may play a valuable role in the 
detection of distant metastases, such as those of the liver, lungs, adrenal glands, 
ovaries, and skeleton. FDG PET may also be helpful in the follow-up of patients 
undergoing chemotherapy, as it allows the identification of early response to treatment 
Finally, some have advocated the use of laparoscopy and laparoscopic ultrasonography 
to detect the presence of intra-abdominal metastases. In one recent series, 
laparoscopic ultrasound provided N- and M-staging that was superior to CT or EUS 21. 
Adding these methods to conventional staging protocols avoids noncurative 
laparotomies in 11%–48% of patients with GI tumors [22]. This isespecially true for 
malignancies that can be palliated nonoperatively [21]. 
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Fig 8 :EUS of the GE junction. 
Fig 9 :Endoscopy showing Poximal 
Fig 10 :Barium Swallow  -
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Fig : 11 Laparoscopy USG – liver 
Fig 12: Diagnostic laparoscopy  - Peritoneal 
Fig 13 :PET – CT fusion imaging  - 
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CLASSIFICATION 
 
 
There has been longstanding confusion in both the classification and treatment of 
carcinomas arising in the area of the gastroesophageal junction. Whereas thoracic 
surgeons treated all esophagogastric tumors as esophageal in origin ,General 
/gastrointestinal (GI) surgeons approached them as gastric cancers. Furthermore, it 
seems that there was little attempt to differentiate tumors arising in the gastric cardia 
from esophageal tumors even though their origin and biologic behavior were different 13 
Thus, in 1997, at the consensus conference of the International Gastric Cancer 
Association (IGCA) and the International Society for Diseases of the Esophagus (ISDE), 
it was agreed that a clear definition and classification of tumors arising near the 
esophagogastric junction was needed14. 
 
Siewert et al14. Developed the most widely adopted classification system for 
adenocarcinomas arising in the proximity of the esophagogastric junction. 
Gastroesophageal junction tumors are defined as being within 5 cm proximal and distal 
of the anatomic cardia.  
 
They are further differentiated into three distinct tumor entities:  
type I (adenocarcinoma of the distal esophagus arising from an area with specialized 
intestinal metaplasia of the esophagus and which may infiltrate the esophagogastric 
junction from above),  
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type II (true carcinoma of the cardia arising from the cardiac epithelium or short 
segments with intestinal metaplasia at the esophagogastric junction, “junctional 
carcinoma”), 
 
 type III (subcardial gastric carcinoma that infiltrates the esophagogastric junction and 
distal esophagus from below)14. 
 
Type I tumors are a distinct entity that should be treated as a distal esophageal 
cancer. Most of these tumors arise from areas of intestinal metaplasia in Barrett’s 
epithelium as a consequence of chronic gastroesophageal reflux. Increased 
surveillance programs have led to the diagnosis of these tumors at an earlier stage, and 
they can occasionally be managed by limited surgical or endoscopic treatment 9.In 
contrast, type III tumors represent  Proximal gastric cancer and should be approached 
in accordance with gastric cancer guidelines9 .The characterization of type II tumors, 
however, remains controversial. Most evidence suggests that these tumors behave 
more like proximal gastric tumors than distal esophageal adenocarcinomas . For 
example, in contrast to patients with type I tumors, only 10% of these patients have 
intestinal metaplasia in the distal esophagus. Furthermore, the lymphatic drainage 
pathways are such that type I tumors tend to drain more toward the mediastinal nodes, 
as well as to the celiac axis, whereas type II and type III tumors preferentially spread to 
the celiac axis nodes9 . 
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2.6 TREATMENT 
 
THERAPEUTIC OPTIONS  
 
  The four therapeutic options for carcinoma of the esophagogastric junction are 
surgery, radiotherapy, chemotherapy, or a combination of methods. In patients who are 
good candidates for surgery and in whom no distant organ metastasis has been 
identified (stages I and II), surgical resection provides the best chance for cure and the 
best palliation when cure is not possible23. Preoperative radiation is useful in stage III 
squamous cell carcinoma and may convert an unresectable lesion into a resectable 
one. Combined chemoradiotherapy has produced, in some studies, complete remission 
in 20% to 30% of patients. Typically, fluorouracil, cisplatin, and mitomycin-C or 
vincristine are given in combination with 2500 to 3000cGy external radiation directed at 
the lesion. This therapy may be given as the sole treatment or preoperatively. 
There is debate whether patients with complete endoscopic disappearance of the tumor 
after chemoradiotherapy should be subjected to resection.  
 
SURGICAL APPROACH 
 
In patients with no evidence of distant metastases and who are fit for surgery, 
surgical resection is the mainstay of therapy for gastroesophageal junction tumors. A 
complete resection of the tumor and its entire lymphatic drainage offers the best hope 
for long-term survival24. Both tumor stage (particularly nodal involvement or N stage) 
and resection margins (R status) are significant prognostic factors. R status has been 
36 | P a g e  
 
the variable most consistently reported to be associated with prognosis and is also the 
variable most likely to be influenced by surgical technique .Achieving an R0 resection 
can be challenging due to the propensity of these tumors for intramural spread as well 
as their proximity to adjacent organs that cannot always be resected en bloc.  
 
Type I tumors are generally treated by total esophagectomy to obtain adequate 
proximal margins and remove all mediastinal lymph nodes. The management of type II 
and III tumors, however, remains controversial .Numerous surgical approaches have 
been reported for type II tumors8,12,24. These include abdominothoracic en bloc 
esophagogastrectomy, subtotal esophagectomy with resection of the proximal stomach, 
total gastrectomy with transhiatal resection of the distal esophagus, and resection of the 
proximal stomach and distal esophagus with esophagogastrostomy23. 
 
Patient factors such as body habitus, prior surgery, and pulmonary function are 
important in selecting the appropriate surgical approach. Although each approach has 
its advantages and disadvantages, no option has demonstrated a clear survival benefit 
over the others provided that adequate margins are obtained and an adequate 
lymphadenectomy is performed. Bile reflux esophagitis can be a difficult problem to 
manage if reconstruction includes an intrathoracic   phagogastrostomy, but complex 
reconstructions with colon or jejunal interpositions carry an even higher morbidity rate. 
Therefore, many surgeons attempt to place the esophagogastric anastomosis in either 
the abdomen or neck and use the gastric remnant as the conduit of choice 9,10,14,27,28.To 
ensure clear margins, intraoperative frozen sections should be used liberally However, 
even frozen section can lead to false-negative results. In a recent study by Ito et al.,a 
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recommendation was made to achieve a gross proximal resection margin length of at 
least  6 cm and a distal resection margin length of at least 4 cm, regardless of tumor 
location.  
 
Surgical Technique98 
 
Transhiatal esophagectomy ( fig 15)without thoracotomy was developed because 
of the pulmonary and intrathoracic leak complications associated with the thoracotomy 
required for transthoracic and en bloc esophagectomies. For transhiatal 
esophagectomy, the entire thoracic esophagus is resected through a widened hiatus 
and reconstructed with the stomach anastomosed to the remaining cervical esophagus 
above the level of the clavicles .The overall in-hospital mortality for transhiatal 
esophagectomy is 5.7% versus 9.2% for transthoracic esophagectomy, with no 
significant difference in 3- and 5-year survival. Advocates of transhiatal esophagectomy 
report a low operative mortality of 2% to 8% and a low anastomotic leak rate of 5% to 
7.9%. Orringer and coauthorsreviewed their 22-year experience with transhiatal 
esophagectomy in 1085 patients. They reported a hospital mortality rate of 4% and an 
average blood loss of less than 700 mL. Anastomotic leak occurred in 13% of patients. 
A modified technique of reconstituting the gastrointestinal tract by switching to a side-to-
side stapled esophagogastric anastomosis has reduced the leak rate to less than 3%. 
 
In performing a transhiatal esophagectomy, the surgeon removes accessible 
cervical, intrathoracic, and intra-abdominal lymph nodes for staging, but a complete en 
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bloc resection of adjacent lymph node-bearing tissue is not accomplished. The 
advantages of this approach include  
(1) a thoracotomy is avoided;  
(2) an intrathoracic esophageal anastomosis is avoided (if a cervical esophagogastric 
anastomotic leak does occur, it is easily drained and rarely causes mediastinitis or fatal 
complications); and (3) no intra-abdominal or intrathoracic gastrointestinal suture lines 
are present. 
 
The transhiatal esophagectomy is performed through an upper-midline 
abdominal and cervical incision without thoracotomy; therefore, the thoracic esophagus 
is resected through the widened diaphragmatic hiatus and the neck. The stomach is 
mobilized by dividing the left gastric and left gastroepiploic vessels, and the right gastric 
and the right gastroepiploic arcades are preserved. Pyloromyotomy and feeding 
jejunostomy are performed routinely.  
 
The entire thoracic esophagus from the level of the clavicles to the cardia is 
resected, while one carefully monitors intra-arterial blood pressure to avoid prolonged 
hypotension from cardiac displacement during the transhiatal esophageal dissection. 
 
The surgical stapler is used to fashion a gastric tube from the greater curvature 
of the stomach while still preserving the entire length. The stomach is mobilized through 
the posterior mediastinum in the original esophageal bed and is anastomosed (hand 
sewn or stapled) to the cervical esophagus. The normal stomach, properly mobilized, 
reaches to the neck in everypatient. For distal-third esophageal tumors localized to the 
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cardia, the high lesser curvature of the stomach is resected 4 to 6 cm beyond the gross 
tumor, while preserving the point on the high greater curvature 
 
LYMPHADENECTOMY 
 
More than two thirds of patients with esophageal and gastric cancers will have 
lymph node metastases at the time of surgery 29. As stated previously, nodal status is 
nearly as important as R status in determining prognosis and treatment for tumors of the 
gastroesophageal junction. Lymphadenectomy(fig 16) improves the accuracy of 
pathologic staging in both gastric and esophageal cancers and provides locoregional 
control30-32 . The optimal extent of a lymphadenectomy and its impact on survival are 
extremely controversial. 
 
In a study by Karpeh et al.33 , patients with stage II and III gastric cancer who had 
fewer than 15 lymph nodes examined had significantly lower 5-year survival rates. This 
finding was confirmed in other studies24,34. Thus, sampling of at least 15 lymph nodes 
and preferably 20–25 lymph nodes is necessary for accurate staging35. 
 
In 2002, de Manzoni et al8. found that stage pN2 and pN3 were grave prognostic 
indicators. In this study, multivariate analysis revealed that the pT category was less 
important than the N category; univariate analysis revealed that survival greater than 3 
years was restricted to pN0 and pN1 subgroups, regardless of the pT status. The 
authors subsequently concluded that chances for cure are limited to pN0 and pN1 
patients8. 
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Fig 15 Trans Hiatal Esophagectomy 
A. Extent of B. Creation Of Gastric Tube  
C. Conduit   D. Esophagogastric Anastomosis  
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There are generally two types of lymphadenectomies (fig 16)performed for 
gastric cancers. A D1 dissection refers to the removal of the stomach and lesser and 
greater omentum with associated N1 lymph nodes (station 1–6 lymph nodes) 36; A D2 
dissection involves a more extensive gastrectomy with removal of N2 lymph node and 
typically includes a splenectomy and distal pancreatectomy30. A final category, the D3 
dissection, would include nodes within the porta hepatis and periaortic regions.  
 
Recent studies 40,41,42,44have shown that a more extensive lymphadenectomy has 
not been proven to confer a survival benefit, this study questions the assertion that a D2 
dissection results in more complications than does a D1 resection. 
 
There is currently not enough evidence to support performing extended 
lymphadenectomies in all patients with tumors at the gastroesophageal junction30 . 
However, extended lymphadenectomy may improve the prognosis of a subgroup of 
patients with gastric or esophageal cancer who have a limited number of positive lymph 
nodes. In addition, despite the fact that D2 lymphadenectomy has not been shown to be 
superior, it does seem to have the advantage of more accurate pathologic staging. As a 
result, some major cancer centers still perform a D2 resection, as supported by the 
National Comprehensive Cancer Network treatment guidelines . 
 
Finally, current research on sentinel node technology may eventually help to 
eliminate the lymphadenectomy controversy 50 - 52.However, the utility and feasibility of 
thistreatment modality remain to be determined. 
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Lymph node stations surrounding the stomach:  
1, right cardial nodes; 
 2, left cardial nodes;  
3, nodes along the lesser curvature;  
4, nodes along the greater curvature;  
5, suprapyloric nodes; 
 6, infrapyloric nodes; 
 7, nodes along the left gastric artery; 
 8, nodes along the common hepatic artery;  
9, nodes around the celiac axis;  
10, nodes at the splenic hilus;  
11, nodes along the splenic artery; 
12, nodes in the hepatoduodenal ligament;  
13, nodes at the posterior aspect of the pancreas head;  
14, nodes at the root of the mesentery;  
15, nodes in the mesocolon of the transverse colon;  
16, para-aortic nodes. 
 
 
 
 
 
 
 
 
Fig. 16 : Gastric cancer lymph node stations 
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2.7 NEOADJUVANT THERAPY 
 
Since carcinomas of the gastroesophageal junction often present at an advanced 
stage, neoadjuvant therapy has many theoretical benefits. Neoadjuvant therapy may 
reduce the size of the tumor, thereby improving chances of an R0 resection; treat 
micrometastases; and allow accurate assessment of the completeness of pathologic 
response, all of which may influence decisions on postoperative treatment53. In addition, 
certain chemotherapeutic agents may have radiosensitizing properties 54,and the 
increased oxygenation of undisturbed tissue in the tumor bed also enhances the effects 
of preoperative radiation therapy 30.However, there is substantial morbidity associated 
with these regimens. Thus, the ISDE/IGCA consensus conference recommended that 
neoadjuvant therapy be restricted to patients with locally advanced tumors of the 
esophagogastric junction where an R0 resection is questionable. 
 
Many phase II trials have investigated neoadjuvant combination therapy using a 
variety of regimens in patients with both resectable and nonresectable disease55-58. 
These trials generally show that neoadjuvant chemotherapy produces extended 
disease-free and overall survival compared with historical controls. It has been found 
that neoadjuvant therapy with a cisplatin-based polychemotherapy regimen followed by 
surgical resection markedly improves survival .Combination therapy clearly leads to 
improved response rates relative to monotherapy. 
 
Some of the original neoadjuvant trials employed fluorouracil,doxorubicin, and 
mitomycin and fluorouracil, doxorubicin, and high-dose methotrexate (FAMTX)60 . Other 
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randomized control studies have confirmed that FAMTX should be the reference 
treatment 61. 
 
Chemoradiotherapy 65plus surgery significantly reduced the 3-year mortality rate 
compared with surgery alone. In addition, preoperative chemoradiotherapy downstaged 
tumors as evidenced by pathologic analysis of resected specimens. Similar to 
Kaklamanos et al. these authors found that the risk for postoperative mortality was 
higher in the group who had neoadjuvant chemoradiotherapy.  
 
Multimodality neoadjuvant therapy should beconsidered in patients with large 
tumors confined to the esophagus and draining lymph nodes67,68 (i.e., clinical or EUS 
T stage _2 or N stage _0) if the patient is a candidate for surgical resection . However, 
although the evidence is promising, it is important to note that one of the reasons 
neoadjuvant therapy may increase survival is that it compensates for inadequate 
surgical resections70-72.  
 
It is imperative that surgeons strive to attain an R0 resection with at least a D1 
lymphadenectomy in patients with resectable disease regardless of whether they had 
preoperative chemoradiotherapy. 
 
  Clearly, more research is needed before there is a definitive stance on the use of 
neoadjuvant therapy for resectable tumors of the gastroesophageal junction83-84.  
The results of these clinical trials and other studies will hopefully offer improved options 
in the management of gastroesophageal cancer. 
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ADJUVANT THERAPY 
 
A successful surgical resection does not always indicate complete cure. In a 
review of 50,169 patients in the U.S. who underwent gastrectomy between 1985 and 
1996 85, patients with stage IA disease (tumor confined to the gastric mucosa) had a 
65% 10-year survival rate. However, patients with more advanced disease had a 
considerably lower 10-year survival rate, ranging from 3% to 42% 85. These rates 
highlight the importance of considering adjuvant treatment in patients with advanced 
stages of gastroesophageal cancer. 
  
Much evidence now supports the use of chemotherapy to improve outcome in 
patients found to have advanced disease at the time of surgery. Even after gastric 
resection with curative intent, there remains a 40%–65% chance of local or regional 
recurrence in the gastric remnant or tumor bed, anastomosis, or regional lymph  
nodes86-89 . 
 
Therefore, locally directed adjuvant therapy plays an important role in patients 
with tumors of the esophagogastric junction85 .Older studies did not show a survival 
benefit when comparing adjuvant chemotherapy with surgery alone90,91 .Incontrast, a 
survival benefit was demonstrated when adjuvant therapy consisted of postoperative 
radiation with or without concomitant fluorouracil92. 
 
The U.S. Intergroup 0116 study was started in 1991 to examine the possible 
benefit of postoperative adjuvant multimodality treatment using radiotherapy and 
leucovorinmodulated fluorouracil47 .After potentially curative resection of gastric cancer, 
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556 patients were randomly assigned to observation or adjuvant chemoradiotherapy. 
Approximately 20% of these patients had lesions present in the gastroesophageal 
junction. Three-year overall and diseasefree survival were significantly better for 
patients in the latter group (52% vs. 41%, respectively, and 49% vs. 32%, respectively) 
showed that the degree of survival benefit for patients with adjuvant therapy was 
identical for both gastric and gastroesophageal junction carcinomas47. 
 
As with rectal and pancreatic cancers, postoperative multimodal therapy 
consisting of regional radiation plus systemic chemotherapy seems to reduce relapse 
risk and prolong survival in patients with tumors of the stomach or esophagogastric 
junction and should thus be considered in high-risk patients [30]. Given the results of 
the Intergroup 0116 study, postoperative chemoradiotherapy is slowly emerging as the 
standard of care in treating gastric cancer. 
 
Future areas of research need to evaluate new chemotherapeutic agents and 
improved modalities of radiation delivery and identify molecular markers that may 
indicate patients who are more likely to benefit from adjuvant therapy. 
 
PALLIATIVE SURGERY 
 
To palliate dysphagia, prevent aspiration, and improve quality of life, various 
endoscopic treatment modalities have been used. These include stents or laser therapy 
for those patients who present at an advanced stage, have poor general physical 
health, or both, and who cannot withstanda palliative operation41 .Mean survival after 
these approaches has been around 140 days93 .Unfortunately, these modalities are 
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occasionally ineffective. In such cases, consideration should be given to feeding tube 
placement or, in rare instances, palliative surgical resection in patients who are 
otherwise fit. 
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Fig 14 : Diagnostic Algorithm for GE 
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Study 
50 | P a g e  
 
AIM OF THE STUDY 
 
 On the basis of Siewart’s classification we present our single institution experience 
in consecutive patients with AEG tumors over a 3 year period.This  study is an audit of 
GE junction adenocarcinomas 
 
Three current questions are addressed: 
 
* Is there a difference between the three types of AEG tumors in respect to surgical   
   epidemiology 
 
* Analysis of surgical treatment strategies based on tumor type? 
 
* Analysis of immediate post op morbidity between the AEG subgroups?  
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STUDY DETAILS 
 
Type of study: Prospective study 
N  :  46 
M : F  : 29 male : 17 female 
Period of Study: June 2005 to August 2007 
Institution \Departments: Department of Surgical Gastroenterology and General       
      Surgery, Government Royapettah Hospital attached to 
                Kilpauk Medical College 
    
Type of Analysis Done: Clinical Data Analysis 
Inclusion:  
All patients diagnosed with  
1. GE junction tumors  
2. Preoperative staging shows operability. 
3. Surgery done with curative intent 
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Exclusion:  
1. Patients with systemic metastases on preoperative staging  
2.  Poor general status precluding an extensive surgical procedure  
3. Patients with Squamous cell carcinoma of the lower esophagus 
4. Patients not willing for surgery. 
Limitations: 
1. Staging methods were inadequate to decide treatment preoperatively in 
some cases. 
2. Survival rates based on type of tumor and treatment strategy could not be 
assessed due to short duration of study. 
3. Due to the limited number of cases in the study statistical analysis could 
not be done 
The cases were studied from the time of admission to discharge and  followed up 
in the outpatient department . All details are meticulously recorded after review in the 
case sheets. Any treatment approach   contemplated or excluded was duly recorded. 
 
All variables pertaining to the patient’s details, presentation, investigations and 
treatment were recorded in preformed worksheet to ensure uniformity in recording and 
to eliminate any bias.  
All information was recorded in a master chart so as to enable early comparison 
and for critical analysis. The details of the patient and the procedure are given in the 
master chart. 
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MANAGEMENT PROTOCOL 
1. Clinical evaluation 
2. Investigations  
a. Invasive and Non invasive 
b. USG abdomen and Pelvis 
c. UGI scopy with biopsy 
d. CECT abdomen and thorax 
3. Assessment of Co – morbid illnesses 
4. Preoperative staging 
5. Treatment modality decided based on Stage of the disease and the physical 
status of the patient. 
6. Surgical approach based on the topographical location of the tumor and the 
feasibility of resection 
7. Complications during immediate post operative period 
8. Follow up in the out- patient department and during re-admissions 
9. post operative adjuvant RT or CT given 
MODE OF PRESENTATION 
Patients with Ca GE junction presented with the following symptoms 
The patients usually presented with  
1. History of  GERD symptoms  
2. Hematemesis / malena  
3. Unexplained Loss of weight 
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4. Mild dysphagia, rare odynophagia 
5. Retrosternal pain 
6. Epigastric  pain 
7. Asymptomatic but with h\o tobacco or alcohol use 
 
For referred patients, the presenting complaint to their primary physician and the 
duration were taken into account . The mean duration of symptoms were then recorded. 
 
EVALUATION 
Almost 50% of the cases are referrals from District Hospitals and Department of 
Medical gastroenterology. 
The evaluation process begins with a full clinical history and a complete physical 
examination. A thorough assessment of associated comorbid illness is done. 
The assignment to each of the Siewart’s sub types is purely morphological/ 
topographical and was in all patients performed based on a combination of  
 
a. contrast radiogram, 
b. endoscopy with orthograde and retroflexed view of the esophagogastric 
junction 
c. computer tomography,  
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OGD is the diagnostic modality of choice. It gives the intraluminal extent of the 
tumor and provides a biopsy for histopathological confirmation.  
Staging and Metastasis screen is done using CECT abdomen and Thorax and 
USG abdomen. 
Preoperative Stage of disease then determines the treatment modality. 
The performance status of the patient is then assessed as it a good indicator of 
surgical outcome and post operative morbidity and mortality. 
In the outpatient setup, a majority of patients with advanced inoperable lesions and 
those who were poor candidates for surgery were referred for palliative care and are not 
included in the study. 
 Surgical   treatment is directed at a reasonably good cure and palliative loco- 
regional control. Symptom control and palliation are the real therapeutic goals for 
nonsurgical measures. 
PREOPERATIVE OPTIMISATION 
In the preoperative setting, proper patient optimsation influences mortality and 
morbidity after major surgery. Therapy consisted of 
• Improving patient nutrition through enteral and parenteral routes 
• Careful monitoring and correction of co morbid conditions which have 
adverse surgical outcomes like diabetes and hypertension 
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• Any major esophageal surgery requires adequate pulmonary function. 
Physiotherapy and pharmacotherapy were used as required to achieve an 
optimal PFT. 
PATHOLOGY 
 The criteria used for histopathological analysis of preoperative endoscopic biopsy 
and postoperative resected specimens were 
 Macroscopic appearance 
 Location of tumor 
 
 Macroscopic appearance 
 
Polypoidal, ulcerative and elevated lesion 
 
 Maximum size of tumor  
 
 
 Microscopic features 
• Degree of tumor differentiation 
• Associated Barett’s metaplasia    
 
SURGICAL TREATMENT STRATEGIES  
 
Surgical treatment strategies based on tumor type allow a differentiated 
approach and result in survival rates superior to those reported with other approaches. 
The choice of the surgical approach was based on the tumor location (AEG Type I, II, or 
III) with the aim to achieve a complete macroscopic and microscopic tumor resection. 
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In general a transhiatal esophagectomy with or without  resection of the proximal 
stomach was the procedure of choice in patients with Type I tumors. 
A partial gastrectomy with transhiatal resection of the distal esophagus was the 
preferred approach in patients with Type III tumors. 
Similarly, in patients with Type II tumors an attempt was made to achieve a 
complete tumor resection via partial gastrectomy with transhiatal resection of the 
esophagus. 
In general a proximal clearance of 2 cm and a distal clearance of 5 cm has been 
followed. The extent of gastrectomy (Total vs partial) is a controversy. 
A neck anastomosis was preferred over an intra- thoracic one . This avoids 
intrathoracic complications of a leak. 
Due to the advanced presentation of these tumors T3 and T4, prognostic staging 
and locoregional control by lymphadenectomy was avoided due to high incidence of 
nodal positivity , clearance affords little benefit in terms of survival. 
 
POSTOPERATIVE COURSE 
Post operative morbidity and mortality in the immediate 30 days were analyzed. 
 
 
. 
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ANALYSIS OF THE STUDY 
AGE INCIDENCE (chart 1) 
AGE I II III Total Percentage 
20- 30 1 1 1 3 6.50 
31-40 4 3 3 10 21.74 
41-50 6 7 2 15 32.61 
51-60 1 4 5 10 21.74 
61-70 2 2 1 5 10.87 
71-80 3 0 0 3 6.52 
TOTAL 100 
 
The cases recorded in this study are between 26 and 75 years of age. Only 3 cases 
aged less than 30 and 3 cases aged more than 70 years. The age incidence noted in 
females is comparatively earlier compared to males (table 3). The age incidence 
correlates with the literature. Highest incidence is noted in the 40 – 60 years of age. 
Mean age of presentation (years ± SD) 
• TYPE I – 48.5 
• TYPE II – 46.9 
• TYPE III – 49 .7 
 
 
60 | P a g e  
 
 
 
 
 
AGE INCIDENCE chart 1 
SEX INCIDENCE chart 2 
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SEX INCIDENCE (chart 2) 
SEX I II III TOTAL NO. 
OF CASES 
PERCENTAGE 
MALE 10 12 7 29 63.04 
FEMALE 7 5 5 17 36.96 
TOTAL 17 17 12 46 100 
 
In Type II tumors there is strong predominance of the male sex. Among the studied 
cases, increased incidence is found in males which correlates with the literature. Here 
the ratio of incidence between the male and female is 1.7:. 1 
Male: Female ratio: 
• TYPE I - 1.4: 1 
• TYPE II – 1.7: 1 
• TYPE III – 1.4: 1 
AGE Male Female TOTAL 
20- 30 2 1 3 
31-40 5 5 10 
41-50 8 7 15 
51-60 8 2 10 
61-70 3 2 53 
71-80 3 - 3 
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There is an earlier incidence of cancer in the female when compared with the 
male. The peak incidence in females is between 35 and 45 years whereas in the male it 
is between 40 – 50 years. 
Adenocarcinoma of the Esophagogastric Junction Results of Surgical Therapy 
Based on Anatomical/Topographic Classification in 1,002 Consecutive Patients 
J. Ru¨diger Siewert, MD, FACS(Hon), FRCS, FASA,* Marcus Feith, MD,* M. Werner, 
and Hubert J. Stein, MD* 
 I II III Total 
Age (mean) 60.1 60.4 62.6 61 
M:F 9.0:1 5.4:1 2.1:1 3.9:1 
Prevalence of 
G3 
51 55.4 71.6 60.2 
 
Compared with a siewart et al trial published in ANNALS OF SURGERY Vol. 232, No. 
3, 353–361 © 2000 
 
1. The incidence of AEG tumors occurs a decade earlier in our study. 
2. The incidence is higher in females  
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PREDISPOSING FACTORS (chart 3) 
Risk factors I Ii III Total no 
of cases 
Percentage 
Smoking 4 7 1 12 26.09 
Alcohol 7 6 6 19 41.30 
Gord 0 4 2 6 13.04 
Malnutrition 3 0 2 5 10.87 
Others 1 0 1 2 4.35 
Nil 3 4 3 10 21.74 
Total     100 
 
Among the cases studied smoking (26%) and alcohol (41%) form the major 
predisposing factors. GERD (13%) forms an important factor in type II and III growths    
( chart4). There is a significant proportion of patients with no risk factors (21 percent).  
MODES OF PRESENTATION 
SYMPTOMS I II III TOTAL PERCENTAGE 
History of GERD 
symptoms  
 
0 4 2 6 13.4 
Hematemesis/melena  
 
3 0 1 4 8.67 
Retrosternal pain 4 2 3 9 19.56 
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No symptoms  
 
2 4 5 11 23.91 
Epigastric pain  
 
4 1 0 5 10.87 
Dysphagia  
 
2 3 1 6 13.04 
Weight loss 4 1 0 5 13.04 
 
The most common presenting symptoms are reflux (13.4%), retrosternal pain  
(19.56%). Twenty three percent of patients presented with no symptoms referred to the 
GE junction. None of the patients presented as emergencies. 
At presentation, at least 30% of the patients will have an incurable disease, and 
30% will be excluded from radical surgery for various reasons. 
SYMPTOMS TOTAL Operable Inoperable Ratio 
History of GERD 
symptoms  
 
6 4 2 0.5 
Hematemesismalena  
 
4 3 1 0.33 
Retrosternal pain 9 5 4 0.8 
No symptoms  
 
11 9 2 0.22 
Epigastric pain  
 
5 4 1 0.25 
Dysphagia  
 
6 4 2 0.5 
Weight loss 5 4 1 0.25 
65 | P a g e  
 
Patients who were asymptomatic at presentation had the lowest incidence of 
inoperability whereas patients with retrosternal pain had highest incidence of 
inoperability ( note that all patients were deemed operable on conventional imaging 
before surgery was planned). 
 
COMORBID CONDITIONS and OPTIMISATION 
 
As the incidence of GE junction tumors is higher in the elderly age group, the co 
existence of age related diseases is high. The preexisting disease together with the 
tumor related complications cause a delay in the preoperative optimization and  
postoperative recovery. Patients with ASA 3 and above were considered unfit for 
surgery. The most common comorbid condition encountered was diabetes and cardiac 
disease. Optimisation resulted in greater pre and post op stay periods in the hospital 
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Chart 3: RISK FACTORS 
Chart 4: RISK FACTORS AND  TUMOR TYPE  
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*The Acute special diet of GRH: 1 L of milk and 6 eggs.  
LOCATION (chart 5) 
Location No of cases Percentage 
I 17 36.96 
II 17 36.96 
III 12 26.08 
 
The incidence of distal esophageal cancer and true cardia cancer were equal in 
the study group (36%).There was lower incidence of these tumors in the proximal 
stomach (26%). 
 No of CASES Investigations Treatment 
givens 
Percentage of 
total patients 
NUTRITION  4 BMI 
Albumin 
Feeding 
jejunostomy 
Maximise oral 
intake 
Acute special 
diet* 
9% 
Cardiac 
disease 
8 ECHO As directed by 
physician 
17.4% 
Diabetes 
mellitus 
8 Serial blood 
glucose 
measurements 
As directed by 
physician 
17.4% 
Poor 
pulmonary 
function 
5 PFT 
 
Chest Physio- 
therapy 
Bronchodilators 
Stop smoking 
 
10.9% 
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chart 4 :PRESENTING SYMPTOMS  AND  TUMOR TYPE   
chart 5 :SIEWART’S TUMOR TYPE  
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HISTOPATHOLOGY  
HISTOPATHOLGY I II III Total Percentage 
Adenocarcinoma 17 17 12 46 100 
Dyplasia - - -  - 
Barett’s esophagus 
(coexisting) 
2 2 - 4 8.7 
GRADE (chart 6)      
G1 11 4 3 18 39.13 
G2 4 9 5 17 36.96 
G3 2 4 4 11 23.91 
Resected margins       
Positive 1 - 1 2 6.0% 
Negative 9 11 8 28 87.5% 
 
ENDOSCOPY (chart 7) 
 
 I 
 
II 
 
III 
 
TOTAL % 
Ulceration  6 3 2 11 23.91 
Polypoid 
mass  
10 11 8 29 63.04 
Sligthly Elevated 
lesion 
 
1 3 2 6 13.05 
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All resection specimen were assessed by an experienced pathologist. Staging is 
reported according to the most recent 2002 version of the UICC/AJCC guidelines. 
 
In 8 % of the patients it was possible to show the presence of intestinal 
metaplasia (Barrett’s esophagus) adjacent to the tumor. In patients with advanced 
tumors an accompanying Barrett mucosa could in some instances not be documented.  
Most type I tumors showed a so-called intestinal growth pattern. In contrast, Barrett’s 
mucosa could not be demonstrated in Type III tumors, while 66% Type III tumors had a 
diffuse growth pattern and 30% were undifferentiated (G3 category) .This is of surgical 
interest regarding the extent of resection. 
 
Most of the lesions were polypoidal in gross morphology (63%). Ulcerated (23%) 
and elevated (13.1%) lesions accounted for the remaining. 
 
The prevalence of undifferentiated tumors, and growth pattern shows more 
similarities between Type II and III tumors than between Type II and I tumors. 
 
  An association between Barrett mucosa and Type I and II cancers could not be 
proven in the vast majority of patients due to the extensive nature of the lesions. 
 
 Esophageal tumors spread directly in longitudinal (oral/aboral) and radial 
directions. Positive resection margins resulting from longitudinal spread have been 
found in 6.0 % of resected specimens . 
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Chart 6: MACROSCOPIC APPEARANCE  
Chart 7: GRADE OF TUMOR 
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SURGERY 
 
Adenocarcinoma of the EsophagogastricJunction Results of Surgical Therapy Based on 
Anatomical/Topographic Classification in 1,002 Consecutive Patients 
J. Ru¨ diger Siewert, MD, FACS(Hon), FRCS, FASA,* Marcus Feith, MD,* M. Werner, 
and Hubert J. Stein, MD* ANNALS OF SURGERY Vol. 232, No. 3, 353–361 © 2000 
 
Resection Reconstruction I II III TOTAL 
Total gastrectomy + 
distal 
esophagectorny 
Roux-en-Y 
esophagojejunostomy 
0 1 2 2 
Proximal 
gastrectomy + 
subtotal 
esophagectomy 
Gastric tube + 
esophagogastrostomy 
1 10 6 17 
Subtotal 
esophagectomy 
(transhiatal) 
Gastric tube + 
esophagogastrostomy 
12 1 0 13 
Laparotomy  Diagnostic 4 5 4 13 
Palliative bypass   1 0 0 1 
TOTAL     46 
Resection I II III TOTAL 
Transthoracic 
Esophagectomy 
 
66 5 1 72 
Transmediastinal 
Esophagectomy 
 
266 43 6 315 
Extended gastrectomy 
29 223 363 615 
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Surgical treatment strategies (chart 8) based on tumor type allow a differentiated 
approach and result in survival rates superior to those reported with other approaches. 
The choice of the surgical approach was based on the tumor location (AEG Type I, II, or 
III) with the aim to achieve a complete macroscopic and microscopic tumor resection. 
In general a radical transhiatal subtotal esophagectomy or en bloc 
esophagectomy with resection of the proximal stomach was the procedure of choice in 
patients with Type I tumors. Combined abdomino-thoracic approach was done in a 
single case due to difficulty in mobilizing the tumor. Unresectability of the lesion was 
found in 23% of tumors. 
 
A Partial gastrectomy with transhiatal resection of the distal esophagus was the 
preferred approach in patients with Type III tumors. 
  
Similarly, in patients with Type II tumors an attempt was made to achieve a 
complete tumor resection via an extended total gastrectomy with transhiatal subtotal 
resection of the esophagus with reconstruction using a tabularized distal stomach. The 
unresectability rate was 29% in type II and 30% in type III tumors. 
 
For those who undergo potentially curative surgical resection, the 5-year survival 
rates are generally only 30%–40%. In many centers worldwide, surgery is considered 
the standard treatment for patients who are medically fit, and in whom a complete (R0) 
resection can be achieved. 
Almost all cases of gastric pull up underwent pyloroplasty as a routine. We 
preferred mostly a midline abdominal incision and a Left neck incision for anastomosis. 
Ninety six % of cases were started on jejunostomy feeds on the 3rd Post operative day 
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Average duration for beginning of oral feeds was 5 days. It was delayed in 2 cases due 
to suspicion of neck leak. 
In spite of effective preoperative evaluation, about 13 cases (28%) posted for 
definitive procedure were found to be inoperable. The signs of inoperability are  
1. Involvement of aorta 
2. Extensive pleural involvement 
3. Ascites 
4. Liver secondaries 
5. Encasement of major vessels  
Hand sewn neck anastomosis is equally found to be effective than staplers. End to side 
anastomosis which is preferred for esophagosatric anastomosis and is associated with 
less postop complications and good quality of life. Studies show morbidity is less with 
hand sewn anastomosis and there is less evidence of neck leak with hand sewn 
anastomosis. 
TOTAL DURATION OF STAY IN THE HOSPITAL 
No of days Preop % Post op Percentage 
< 10 days 12 26.09 18 39.13 
< 20 days 12 26.09 17 36.96 
< 30 days 13 28.26 9 19.57 
< 40 days 8 17.39 2 4.34 
> 40  days 1 2.17 0 0 
Median duration of preoperative hospitalization was 21.09 days(range 4- 44 
days). Median duration of postoperative hospitalization was 16.37 days (range, 7–40 
days). Two patients died on 3rd and 20th  post operative day respectively. 
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OUTCOME AFTER SURGICAL RESECTION  
The incidence of postoperative complications is summarized in chart 9. 
POSTOPERATIVE 
COMPLICATION 
OG 
GPT 
THE 
GPT 
DE + TG 
EJ 
Total 
Wound infection 2 3 1 6(18.18%) 
Anastomotic leak 1 1 - 2(6%) 
Respiratory complication 3 1 - 4(12.12%) 
Cardiac complications 1 - - 1(3%) 
30 day mortality 1 1 - 2 (6%) 
Overall  - - - 15 (45.5%) 
 
The overall 30 day postoperative mortality after surgical resection was 2 patients 
(6%) , one developed respiratory failure due to pneumonia and the other died from 
myocardial infarction. 
 
Patients with anastomotic leakage (6%) were successfully treated by 
postponement of oral feeding.  
 
ADJUVANT THERAPY 
 
All patients with resectable disease were given post operative radiotherapy. This 
has limited the number of recurrence to 3 patients in the mean follow period of 12 
months (range 2 to 32 months) 
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Chart 8 SURGERY AND  TUMOR TYPE 
Chart 9 TYPE OF SURGERY AND POST OPERATIVE COMPLICATIONS 
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PALLIATIVE CARE 
 
 
For patients whose disease could not be completely resected, 13 patients 
(28.2%) radiation therapy was the mainstay of treatment for patients who had locally 
advanced disease with no evidence of distant metastases. Feeding tubes were used for 
palliation of dysphagia in all 13 patients.  
 
LONG TERM SURVIVAL 
  
 
 
The mean duration of follow up was 5.35 months range from 1 to 32 months. 
During follow- up, 3 patients developed tumor recurrence of which they subsequently 
died (at 10, 15, and 32 months after surgery). Recurrences were initially detected as 
malignant pleural effusion, as bone metastases, or as anastomotic recurrence in 
combination with mediastinal lymph node involvement, respectively. In all three patients, 
the primary lesion had invaded the submucosal layer and lymph node metastasis was 
present at the time of esophagectomy.  One patient died 26 months after resection of an 
intramucosal carcinoma without clinical signs of tumor recurrence (the patient had a 
history of cerebrovascular disease, which was the probable cause of death).  Seven 
patients lost followup. Twenty-two patients were alive without recurrent disease after a 
median follow-up of 12 months (range, 2–32 months). The follow up period is too short 
to determine survival rate and long term prognosis. However the initial rates of survival 
were comparable to the Siewart’s study. 
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Discussion & 
Summary 
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DISCUSSION 
 
  Our experience with 46 AEG tumors indicates that the subtypes differ in terms 
of epidemiology and histomorphologic tumor characteristics. In terms of surgical 
epidemiology Type II tumors are somewhere in the middle between Type I and III but 
with more resemblance to Type III than Type I tumors. 
 
The preoperative staging of GE junction tumors needs careful review as a 
significant propotion of patients were diagnosed intraoperatively. Diagnostic 
lasparoscopy may be useful adjunct in predicting inoperability. 
 
The analysis confirms, that a selection of the treatment strategy based on tumor 
type is justified  .Surgical therapy of the various esophago–gastric junction tumors has 
now been standardized and can be performed with minimal risk for the patient.  
 
This is underlined by the low postoperative mortality achieved in our population. 
Regarding the discussion on the most appropriate surgical procedure for esophago–
gastric junction tumors, our data confirm that a discriminate approach is justified. 
  
It is uniformly accepted that patients with AEG Type I tumors require an 
transhiatal esophagectomy in our population has shown good results in terms of 
minimum postoperative complications and   long-term survival.  The advantage over a 
intra thoracic anastomosis is that a neck anastomsis avoids complications due to an 
intra thoracic leak and allows early detection of anastomosis.  
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Partial  gastrectomy with sub total esophagectomy is the procedure of choice 
 for type II and III tumors at our institution. It is still an open question, whether an 
extended total gastrectomy is required for Type II tumors or whether a proximal 
gastrectomy with distal esophageal resection suffices  
 
Provision of a good proximal and distal clearance is, however, mandatory when 
performing surgery in any tumor type. Feeding jejunostomy is a quick and 
uncomplicated  procedure is a routine in this department. Its uses are 
 
• Early postoperative nutrition  
• To tide over an for anastomotic leak  should it occur  
• as palliation for dysphagia and is recommended in all patients  
 
In the immediate postoperative period our mortality and morbidity rates are 
comparable to centres elsewhere and emphasizes the importance of good patient 
selection and preparation. 
 
The analysis of outpatient population shows that postoperative mortality and 
long-term survival results were too short to compare survival rates  reported in the 
literature. The overall prognosis is yet to be determined.  
 
Our own experience with lymphadenectomy in our patients is limited.  
1. Due to overall increase in morbidity and mortality to the patient 
2. Due to the advanced nature of lesions we see, studies have shown that there 
is no overall improvement in survival  
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The value of multimodality therapy in patients with advanced tumors is being 
studied in our department currently. 
 
Taken together, the selection of the surgical procedure based on the AEG Type I, 
II, and III classification of esophago–gastric junction tumors has proven valuable and 
results in good surgical outcomes. The subclassification of AEG tumors thus provides a 
useful tool for the selection of the surgical procedure and allows a better comparison of 
treatment results. 
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CONCLUSION 
 
 
Tumors of the esophagogastric junction seem to be a distinct pathophysiologic 
entity, separate from esophageal and gastric carcinomas yet with some oncologic 
features of each. The classification of adenocarcinomas arising at or close to the 
esophago–gastric junction into Type I, II, and III tumors, originally introduced in 1987 
has stood the test of time .The classification is practical and useful for the selection of 
the surgical approach and the extent of resection. Consequently it is increasingly 
employed worldwide .This results in a better understanding of the biology of these 
tumors and allows comparison of treatment results for the various tumor types between 
centers. 
 
Accurate preoperative staging is crucial in the management of these tumors. 
Patients can be divided into two broad categories: those with resectable disease versus 
those with unresectable disease. Among the former group, the mainstay of treatment is 
surgical resection. The surgical strategy using differentiated approach is practical. The 
post operative morbidity is similar in the various surgical modalities and much emphasis 
lies on careful patient selection. The goal is an R0 resection with associated adequate 
lymphadenectomy. Patient and tumor characteristics help determine the optimal 
surgical approach for achieving R0 status..  Multimodal adjuvant therapy should be 
used liberally in patients to prevent post operative recurrence. Postoperative multimodal 
adjuvant therapy is beneficial in patients who are at high risk of local failure or of 
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developing systemic disease. In general, patients who may benefit from either 
neoadjuvant or adjuvant therapy should be encouraged to enroll in ongoing trials.  
 
For patients whose disease cannot be completely resected, alternative measures 
exist for palliation of symptoms and control of local disease. Radiation therapy should 
be a mainstay for patients who have locally advanced disease with no evidence of 
distant metastases. Endoluminal stents and feeding tubes can be important tools for 
palliation of dysphagia. In advanced lesions, one must carefully consider the risks and 
morbidity of aggressive intervention versus the nonsurgical alternatives to palliate 
symptoms and provide the best quality of life for the patient. 
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ABBREVIATIONS AND KEY TO THE MASTER CHART 
GE junction:  Gastroesophageal junction 
GERD:   Gastroesophageal reflux disease 
OGD:    Esophagogastroduodenoscopy 
CT:    Computerized Tomogram 
USG:    Ultrasonogram 
DOA: DATE OF ADMISSION 
DOS : DATE OF SUREGRY 
DOD: DATE OF DISCHARGE 
G: GRADE 
AC: ADENOCARNIMOMA 
Sm: SMOKER 
Al: ALCOHOLIC 
GORD: GASTROESOPHAGEAL REFLUX DISEASE 
Mal: MALNUTRITION 
RP: RESTROSTERNAL CHEST PAIN 
Dys: DYSPHAGIA 
Wl: WEIGHT LOSS 
Epi: EPIGASTRIC PAIN 
Dia: DIABETES 
IHD: CARDIAC DISEASE 
P: PROLIFERATIVE 
U: ULCERATIVE 
E: ELEVATED 
TG Reux EJ: trans hiatal esophagectomy with refux esophagojejunostomy 
OG GPT: oesophagogastrectomy with gastric pull through 
Inop: Inoperable 
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THE GPT: trans hiatal esophagectomy with gastric pull through 
Pall Colo: Palliative coloplasty 
PG OG: partial gastrectomy with esophagogasric anastomosis 
W: WOUND INFECTION 
R: RESPIRATORY COMPLICATION 
C: CARDIAC COMPLICATION 
D: DEATH 
N\RT: NO OF MONTHS FOLLOWUP \RT 
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PROFORMA FOR THE STUDY OF GASTROESOPHAGEAL MALIGNANCIES 
 
NAME:     I.P. NO:    CASE NO: 
AGE:     UNIT: 
SEX: 
I. PRESENTING COMPLAINTS 
History of GERD symptoms   
Hematemesis/melena  
Retrosternal pain  
No symptoms   
Epigastric pain   
Dysphagia   
Weight loss  
 
II. PAST HISTORY 
III. PERSONAL HISTORY 
SMOKING   
ALCOHOL  
GORD  
MALNUTRITION  
OTHERS  
NIL  
 
IV. TREATMENT HISTORY 
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V. GENERAL EXAMINATION 
BUILD  
NOURISHMENT  
PERFORMANCE STATUS  
PALLOR  
ICTERUS  
CYANOSIS  
PEDAL EDEMA  
LYMPHADENOPATHY  
VITALS  
PULSE RATE  
RESPIRATORY RATE  
BLOOD PRESSURE  
 
VI. LOCAL EXAMINATION: 
ASCITES  
HEPATOMEGALY  
PERRECTAL EXAM  
 
VII. OTHER SYSTEMS 
CVS  
RS  
SPINE, CRANIUM,LONG BONES  
 
VIII. SPECIALIST OPINION 
CARDIOLOGY  
DIABETOLOGY  
PULMONOLOGY  
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IX. BASIC INVESTIGATIONS 
HB% / PCV  
TC /DC  
ESR  
UREA, CREATININE  
BLOOD SUGAR  
LIVER FUNCTION TEST  
ECG  
CHEST AND ABDOMINAL SKIAGRAM  
 
X. SPECIAL INVESTIGATIONS 
BARIUM SWALLOW  
ENDOSCOPY 
LOCATION 
EXTENT 
 
HISTOPATHOLOGY 
CELL TYPE 
GRADE 
 
 
 
CT ABDOMEN  
CT THORAX  
POST OP HISTOPATHLOGY  
 
XI. DIAGNOSIS 
XII. TREATMENT 
PRESURGERY STAY  
PREOPTIMISATION  
RESECTABLE OR NOT  
TYPE OF RESECTION  
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TYPE OF RECONSTRUCTION  
INTRAOP COMPLICATIONS  
POSTSURGERY STAY  
POSTOP COMPLICATIONS  
 
XIII. FOLLOW UP 
POST OP ADJUVANT THERAPY  
DURATION OF FOLLOW UP  
COMPLICATIONS  
RECURRENCE  
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